Compounds > rosiglitazone
Page last updated: 2024-08-25

rosiglitazone and Skin Neoplasms

rosiglitazone has been researched along with Skin Neoplasms in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Goepfert, C; Hafner, J; Jandus, C; Levesque, MP; Loyon, R; Mastelic-Gavillet, B; Meylan, P; Michalik, L; Moret, C; Moser, H; Nguyen, TN; Pich, C; Romero, P; Trang, BK1
Tseng, CH1
Füzesi, L; Krüger, U; Middel, P; Mössner, R; Neumann, C; Reich, K; Schinner, S; Schulz, U1
Fischer, SM; He, G; Lubet, RA; Muga, S; Thuillier, P1
Digiovanni, J; Fischer, SM; He, G; Sung, YM1

Other Studies

5 other study(ies) available for rosiglitazone and Skin Neoplasms

ArticleYear
Induction of Paracrine Signaling in Metastatic Melanoma Cells by PPARγ Agonist Rosiglitazone Activates Stromal Cells and Enhances Tumor Growth.
    Cancer research, 2018, 11-15, Volume: 78, Issue:22

    Topics: Angiogenesis Inducing Agents; Animals; Carcinogenesis; Cell Line, Tumor; Fibroblasts; Human Umbilical Vein Endothelial Cells; Humans; Inflammation; Leukocytes, Mononuclear; Macrophages; Melanoma; Mice; Mice, Inbred NOD; Mice, SCID; Monocytes; Neoplasm Metastasis; Neoplasm Transplantation; Oligonucleotide Array Sequence Analysis; Paracrine Communication; PPAR gamma; Rosiglitazone; Skin Neoplasms; Stromal Cells; T-Lymphocytes

2018
Rosiglitazone may reduce non-melanoma skin cancer risk in Taiwanese.
    BMC cancer, 2015, Feb-06, Volume: 15

    Topics: Adult; Aged; Aged, 80 and over; Comorbidity; Databases, Factual; Female; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Risk; Rosiglitazone; Skin Neoplasms; Taiwan; Thiazolidinediones; Young Adult

2015
Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma.
    The Journal of investigative dermatology, 2002, Volume: 119, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Cell Division; Chromans; Dose-Response Relationship, Drug; Fibrinolytic Agents; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors; Melanoma; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Skin Neoplasms; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Tumor Cells, Cultured

2002
The effect of PPARgamma ligands on UV- or chemically-induced carcinogenesis in mouse skin.
    Molecular carcinogenesis, 2005, Volume: 43, Issue:4

    Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Carcinogens; Cell Proliferation; Cell Transformation, Neoplastic; Chromans; Diet; Female; Keratinocytes; Ligands; Mice; PPAR gamma; RNA, Messenger; Rosiglitazone; Skin Neoplasms; Tetradecanoylphorbol Acetate; Thiazolidinediones; Troglitazone; Ultraviolet Rays

2005
Thiazolidinediones inhibit insulin-like growth factor-i-induced activation of p70S6 kinase and suppress insulin-like growth factor-I tumor-promoting activity.
    Cancer research, 2006, Feb-01, Volume: 66, Issue:3

    Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Cell Growth Processes; Chromans; Enzyme Activation; Humans; Insulin-Like Growth Factor I; Keratinocytes; Mice; Mice, Transgenic; Multienzyme Complexes; Phosphorylation; Protein Kinases; Protein Serine-Threonine Kinases; Ribosomal Protein S6 Kinases, 70-kDa; Rosiglitazone; Signal Transduction; Skin Neoplasms; Thiazolidinediones; TOR Serine-Threonine Kinases; Transfection; Troglitazone

2006